PharmacoEconomics

, Volume 23, Issue 9, pp 875–888

Economic implications of biological therapies for Crohn’s disease

Review of infliximab
Review Article

Abstract

Crohn’s disease is a chronic, relapsing inflammatory bowel disease that may require extensive medical and surgical interventions. Traditional therapies include 5-aminosalicylates, corticosteroids, immunosuppressants (e.g. azathioprine, mercaptopurine), defined formula diets, antibacterials and surgery. Infliximab is an anticytokine therapy for Crohn’s disease that targets tumour necrosis factor-α. Infusions of infliximab have been shown to be superior to placebo in the induction and maintenance of remission in moderately severe and/or fistulising Crohn’s disease. This review briefly summarises the data for clinical effectiveness of infliximab and then considers the economic implications of its use.

Available economic modelling exercises suggest that infliximab has a relatively high incremental cost per QALY compared with standard care. However, there are limitations to these theoretical data and there has been no direct assessment of cost effectiveness within a controlled trial. Effective alternative treatment options for moderate-to-severe Crohn’s disease are relatively lacking. More data are needed relating to the long-term safety of infliximab and the extent to which this new biological therapy produces lasting clinical benefits.

References

  1. 1.
    Ward FM, Bodger K, Daly MJ, et al. Clinical economics review: medical management of inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 15–25PubMedCrossRefGoogle Scholar
  2. 2.
    Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003; 3: 81–92PubMedGoogle Scholar
  3. 3.
    van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129–35PubMedCrossRefGoogle Scholar
  4. 4.
    Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 1995; 30: 699–706PubMedCrossRefGoogle Scholar
  5. 5.
    Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49–57PubMedCrossRefGoogle Scholar
  6. 6.
    Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn’s disease: based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146–50PubMedCrossRefGoogle Scholar
  7. 7.
    Bebb JR, Scott BB. How effective are the usual treatments for Crohn’s disease? Aliment Pharmacol Ther 2004; 20: 151–9PubMedCrossRefGoogle Scholar
  8. 8.
    Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723–9PubMedCrossRefGoogle Scholar
  9. 9.
    Bell SJ, Kamm MA. Review article: the clinical role of antiTNFalpha antibody treatment in Crohn’s disease. Aliment Pharmacol Ther 2000; 14: 501–14PubMedCrossRefGoogle Scholar
  10. 10.
    Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn’s disease. J Clin Immunol 1996; 16: 144–50PubMedCrossRefGoogle Scholar
  11. 11.
    Louis E, Peeters M, Franchimont D, et al. Tumour necrosis factor (TNF) gene polymorphism in Crohn’s disease (CD): influence on disease behaviour? Clin Exp Immunol 2000; 119: 64–8PubMedCrossRefGoogle Scholar
  12. 12.
    Negoro K, Kinouchi Y, Hiwatashi N, et al. Crohn’s disease is associated with novel polymorphisms in the 5’-flanking region of the tumor necrosis factor gene. Gastroenterology 1999; 117: 1062–8PubMedCrossRefGoogle Scholar
  13. 13.
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 1029–35PubMedCrossRefGoogle Scholar
  14. 14.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398–405PubMedCrossRefGoogle Scholar
  15. 15.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9PubMedCrossRefGoogle Scholar
  16. 16.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876–85PubMedCrossRefGoogle Scholar
  17. 17.
    Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761–9PubMedCrossRefGoogle Scholar
  18. 18.
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 402–13PubMedCrossRefGoogle Scholar
  19. 19.
    Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593–610PubMedCrossRefGoogle Scholar
  20. 20.
    Bodger K. Cost of illness of Crohn’s disease. Pharmacoeconomics 2002; 20: 639–52PubMedCrossRefGoogle Scholar
  21. 21.
    Feagan BG. Review article: economic issues in Crohn’s disease: assessing the effects of new treatments on health-related quality of life. Aliment Pharmacol Ther 1999; 13 Suppl. 4: 29–37PubMedCrossRefGoogle Scholar
  22. 22.
    Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn’s disease. Am J Gastroenterol 2000; 95: 524–30PubMedCrossRefGoogle Scholar
  23. 23.
    Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol 2000; 95: 1955–60PubMedCrossRefGoogle Scholar
  24. 24.
    Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14: 318–27PubMedCrossRefGoogle Scholar
  25. 25.
    Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992; 14: 309–17PubMedCrossRefGoogle Scholar
  26. 26.
    Bassi A, Dodd S, Williamson P, et al. Cost-of-illness of inflammatory bowel disease in the United Kingdom: a single-centre retrospective study. Gut 2004; 53 (10): 1471–8PubMedCrossRefGoogle Scholar
  27. 27.
    Monthly Index of Mechanical Specialities (MIMS). London: Haymarket Medical Publications Ltd., 2004Google Scholar
  28. 28.
    Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 2000; 95: 677–83PubMedCrossRefGoogle Scholar
  29. 29.
    Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004; 99: 91–6PubMedCrossRefGoogle Scholar
  30. 30.
    Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol 2002; 35: 151–6PubMedCrossRefGoogle Scholar
  31. 31.
    Jewell DP, Probert CSJ, Lobo AJ, et al. The effect on health care resources of infliximab use in Crohn’s disease [abstract]. Gastroenterology 2004; 126 (4 Suppl. 2): S1218Google Scholar
  32. 32.
    National Institute for Clinical Excellence. Full guidance on the use of infliximab for Crohn’s disease (Technology Appraisal Guidance No. 40), 2002 [online]. Available from URL: http://www.nice.org.uk/page.aspx?0=31337 [Accessed 2005 Jan 1]Google Scholar
  33. 33.
    Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol Assess 2003; 7: 1–67PubMedGoogle Scholar
  34. 34.
    Marshall JK, Blackhouse G, Goeree R, et al. Clinical and economic assessment: infliximab for the treatment of Crohn’s disease. Technology Overview No. 8. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2002Google Scholar
  35. 35.
    Arseneau KO, Cohn SM, Cominelli F, et al. Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 2001; 120: 1640–56PubMedCrossRefGoogle Scholar
  36. 36.
    Jaisson-Hot I, Flourie B, Descos L, et al. Management for severe Crohn’s disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004; 20 (3): 274–9PubMedCrossRefGoogle Scholar
  37. 37.
    Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurement in Crohn’s disease. Inflamm Bowel Dis 1997; 3: 265–76Google Scholar
  38. 38.
    Hilsden R. Funding the new biologics: what can we learn from infliximab? The CCOHTA report: a gastroenterologist’s viewpoint. Can J Gastroenterol 2002; 16: 865–8PubMedGoogle Scholar
  39. 39.
    Lewis S. Funding the new biologics: public policy issues in drug formulary decision making. Can J Gastroenterol 2002; 16: 869–72PubMedGoogle Scholar
  40. 40.
    Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19–31PubMedCrossRefGoogle Scholar
  41. 41.
    Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13 Suppl. 4: 16–22PubMedCrossRefGoogle Scholar
  42. 42.
    Schaible TF. Long term safety of infliximab. Can J Gastroenterol 2000; 14 Suppl. C: 29C–32CPubMedGoogle Scholar
  43. 43.
    Arend SM, Breedveld FC, van Dissel JT. TNF-alpha blockade and tuberculosis: better look before you leap. Neth J Med 2003; 61: 111–9PubMedGoogle Scholar
  44. 44.
    Bickston SJ, Lichtenstein GR, Arseneau KO, et al. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology 1999; 117: 1433–7PubMedCrossRefGoogle Scholar
  45. 45.
    Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151–8PubMedCrossRefGoogle Scholar
  46. 46.
    Lyseng-Williamson KA, Foster RH. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004; 22: 107–32PubMedCrossRefGoogle Scholar
  47. 47.
    Milton CR. A health economic critique of the CCOHTA report: infliximab for the treatment of Crohn’s disease. Can J Gastroenterol 2002; 16: 873–6Google Scholar
  48. 48.
    Cohen RD. IBD indirect costs: the sleeping giant? Gastroenterology 2003; 125: 982–4PubMedCrossRefGoogle Scholar
  49. 49.
    Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn’s disease. Inflamm Bowel Dis 2002; 8: 237–43PubMedCrossRefGoogle Scholar
  50. 50.
    Bassi A, Dodd S, Williamson P, et al. Health state utilities and willingness-to-pay in inflammatory bowel disease: a study of feasibility and validity [abstract]. Aliment Pharmacol Ther 2005; 21: 197CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Gastroenterology Division, School of Clinical SciencesUniversity of LiverpoolLiverpoolUK
  2. 2.Aintree Centre for GastroenterologyUniversity Hospital AintreeLiverpoolUK
  3. 3.Department of Medicine, Clinical Sciences CentreUniversity Hospital Aintree, Lower LaneLiverpoolUK

Personalised recommendations